Kennedy Appeals Ruling Halting ACIP Reforms on Childhood Vaccine Schedule

The June 2026 district court order blocked Kennedy’s directive to reconstitute ACIP membership and review the pediatric schedule for hepatitis B, rotavirus, and other antigens. Court filings show the panel was prevented from voting on four agenda items scheduled for July. Primary source reporting confirms the injunction rested on Administrative Procedure Act claims that the secretary exceeded statutory authority without new evidence of risk-benefit changes.

Observational data from CDC’s Vaccine Safety Datalink through 2025 show no population-level increase in the targeted diseases, yet coverage for MMR and DTaP has declined 3–5 percentage points in states with recent exemption expansions. Historical precedent from the 2019–2020 measles outbreaks demonstrates that coverage drops below 92 % correlate with sustained transmission; current modeling projects similar thresholds could be reached within 18 months if ACIP recommendations remain stalled.

The litigation intersects broader federal signals: reduced emphasis on universal hepatitis B birth-dose language and proposed narrowing of school-entry requirements. These moves parallel state-level bills in Texas and Florida that reference federal advisory uncertainty. No peer-reviewed analysis has yet quantified net population impact, leaving open whether observed coverage erosion reflects policy signals or pre-existing trends.

Next steps hinge on the appeals court schedule; expedited briefing could yield a decision by October 2026. Parallel proceedings in two additional districts may produce conflicting injunctions, increasing the likelihood of Supreme Court review before the 2027–2028 school year.